Pharmaceuticals

2025 Analysis: Opportunities and Risks in the Evolving Inhalation CDMO Market

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#How Will the Inhalation CDMO Market Evolve in Terms of Growth and Size by 2029?#_x000D_

The size of the roxadustat market has demonstrated robust growth in the past few years. The market is set to expand from $6.44 billion in 2024 to $6.86 billion in 2025, displaying a compound annual growth rate (CAGR) of 6.5%. The historic period’s growth was driven by factors such as receiving regulatory approvals in significant markets, successful clinical test results, an escalating rate of chronic kidney disease, heightened consciousness regarding anemia management, and governmental backing for anemia treatments._x000D_

_x000D_

The market size for roxadustat is predicted to experience robust expansion over the next couple of years, climbing to a value of “$8.95 billion in 2029 with a compound annual growth rate (CAGR) of 6.9%. This upswing during the forecasted timeframe is linked to continued studies into new usage areas, escalated healthcare spending, the market demand for anemia treatments that don’t involve injections, broadening insurance coverage policies, and an increasing elderly population. The principal trends anticipated in this same period consist of a migration towards oral anemia therapies, intensifying competition from other treatment methods, expanding licensing contracts, rising investment into research around hypoxia-inducible factors, and an emphasis on treatments centred around patients._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp_x000D_

_x000D_

#What factors are expected to fuel Inhalation CDMO market growth in the coming years?#_x000D_

The rise in respiratory disease occurrences is anticipated to stimulate the expansion of the inhalation CDMO market. Respiratory conditions encompass a variety of health issues impacting the respiratory system, including all organs and structures used in breathing. The knowledge and proficiency of inhalation CDMOs in devising and distributing drugs to the lungs make them instrumental in developing and manufacturing treatments for respiratory disorders. This provides pharmaceutical firms with specialized expertise, infrastructure, and resources needed for creating groundbreaking inhalation therapies. For example, the Australian Bureau of Statistics (ABS), a government agency in Australia, reported that 8.5 million Australians, or 34%, suffer from chronic respiratory diseases, which include 2.8 million, or 11%, with asthma, and 638,000, or 2.5% with COPD. The surging prevalence of such respiratory ailments is thus fuelling the growth of the inhalation CDMO market._x000D_

_x000D_

The roxadustat market covered in this report is segmented – _x000D_

_x000D_

1) By Type: 20mg, 50mg_x000D_

2) By Product Formulation: Oral Tablets_x000D_

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers_x000D_

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions_x000D_

_x000D_

#What Trends Are Currently Influencing Growth In The Inhalation CDMO Market?#_x000D_

Prominent organizations in the Roxadustat market are pursuing reimbursement through the high-tech drugs scheme. This strategy aims to extend patient reach by diminishing financial constraints, prompting quicker market assimilation and illustrating the cost-effectiveness of their pioneering treatments. The high-tech drugs scheme is a state-operated initiative, chiefly in Ireland, which offers compensation for the provision of costly, highly specialized medicines usually recommended in hospital contexts. For example, in September 2022, the US-based Astellas Pharma Company Ltd. disclosed that its EVRENZO (Roxadustat) has been awarded reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the inaugural medication of a fresh series of orally ingested hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors to be licensed and compensated in Ireland. The findings affirmed that Roxadustat was potent in accomplishing and preserving target hemoglobin concentrations (10-12g/dL) in individual suffering symptomatic anemia of CKD, independent of dialysis status and preceding ESA therapy._x000D_

_x000D_

#What Are The Most Active Companies In The Inhalation CDMO Market Today?#_x000D_

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd. _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report_x000D_

_x000D_

#Which Regional Markets Are Attracting The Most Investment In Inhalation CDMO?#_x000D_

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_